Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Press Releases
Press Release
Share
Press Release
Oct 16, 2019
| Rachel Schwartz
AAM Reaction to FDA Statement on Patient Access to Generic Drugs
Press Release
Oct 8, 2019
| Rachel Schwartz
AAM Response to CA Governor Newsom Signing AB 824
Press Release
Sep 20, 2019
| Rachel Schwartz
Seniors Denied Access to New, Lower-Priced Generic Drugs Due to Medicare Coverage Delays
Press Release
Jul 23, 2019
| Rachel Schwartz
AAM Applauds Senate Finance’s Meaningful Effort to Reduce Drug Prices for America’s Patients
Press Release
Jul 2, 2019
| Rachel Schwartz
National Survey Finds Significant Voter Opposition to Patent Settlement Legislation
Press Release
Jun 26, 2019
| Rachel Schwartz
AAM Applauds Sens. Cornyn and Blumenthal’s Efforts to Accelerate Access to More Affordable Biosimilar Medicines
Press Release
Jun 26, 2019
| Jewel Smith
AAM Announces New 2019 Members
Press Release
May 23, 2019
| Rachel Schwartz
AAM Statement on FTC Report on Patent Settlements
Press Release
May 21, 2019
| Rachel Schwartz
AAM Statement on House Bills 965, 1499 and 938
Press Release
May 17, 2019
| Rachel Schwartz
AAM Statement on the Importance of Generic and Biosimilar Quality and Robust Competition
Press Release
May 16, 2019
| Rachel Schwartz
How Generic Drug Makers Are Responding to Price-Fixing Lawsuit
Press Release
May 13, 2019
| Rachel Schwartz
The 11th Annual Edition of AAM Access & Savings Report Finds Generic Savings Totaled $293 Billion in 2018
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action